1.1Transient FAH messenger RNA
Lipid nanoparticles deliver capped, polyadenylated FAH messenger RNA to host hepatocytes. Ribosomes translate the delivered RNA, and the amount of supplemental FAH falls as the RNA and protein turn over.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Lipid nanoparticles deliver capped, polyadenylated FAH messenger RNA to host hepatocytes. Ribosomes translate the delivered RNA, and the amount of supplemental FAH falls as the RNA and protein turn over.
A constitutive promoter drives an FAH cassette containing a synthetic intron with a stop-containing exon. A splice-switching oligonucleotide masks a splice site of that exon, promotes exon skipping, and restores the FAH reading frame in mature messenger RNA.
A small-molecule inhibitor blocks 4-hydroxyphenylpyruvate dioxygenase upstream of FAH and reduces the formation of fumarylacetoacetate. Withdrawing the inhibitor restores pathway flux and favors transplanted hepatocytes with functional FAH.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
The inducible FAH arrangement supplies expanded primary human hepatocytes for food chemistry studies. The recovered hepatocytes are plated in multiwell culture plates and exposed to purified dietary compounds alongside vehicle controls. Liquid chromatography tracks the disappearance of each parent compound and the appearance of its metabolites.
A microcontroller and a two-position switch replace the inducible promoter and chemical inducer in a bench simulator. The switch supplies the inducer state, and the microcontroller updates a numerical FAH state using separate rise and fall time constants. A digital-to-analog converter sends the simulated FAH signal to the monitoring hardware for testing.
A downstream enzyme assay uses either a 96-well plate with 100 microliters per well or a 384-well plate with 25 microliters per well. Each format receives the same concentration of recovered hepatocytes and the same substrate concentration. The calculation divides the measured product formation rate by the viable cell count in each well.
A single-pass perfusion system receives hepatocytes recovered from the bioincubator. A pump moves medium from a reservoir through a bubble trap and a cell chamber with a collagen-coated growth surface. An outlet sampler collects effluent for albumin and urea measurements, and the measured flow rate converts concentrations to secretion rates.
A laboratory database links inducer administration records and FAH assay results to the same animal identifier. Software aligns records by timestamp and plots measured FAH values against the recorded inducer state. The dashboard flags missing samples and displays albumin and bilirubin measurements on separate tracks for review.
A slide scanner captures liver sections stained for a donor-specific nuclear marker and a general nuclear counterstain. Image analysis segments nuclei in the counterstain channel and classifies each nucleus using the signal from the donor marker channel. Software reports the fraction of nuclei positive for the donor marker by section and links the results to the corresponding FAH measurements.
A constitutive promoter produces FAH fused to a tag that recruits a cellular ubiquitin ligase in the presence of a small molecule. Dosing directs the tagged FAH to the proteasome, and withdrawal lets newly synthesized FAH accumulate.
A constitutive liver promoter sits upstream of an FAH coding sequence separated by a transcriptional stop cassette. Recombinase translated from delivered messenger RNA excises the stop cassette at paired recognition sites, and FAH transcription continues after the recombinase clears.
An integrated cassette places an FAH coding sequence downstream of tetracycline operator repeats and a minimal promoter. A separate hepatocyte-active promoter supplies a reverse tetracycline-responsive transactivator that binds the operators in the presence of a tetracycline-class inducer.
A tetracycline-responsive promoter replaces the native promoter at the endogenous FAH locus. The replacement promoter drives transcription through the existing FAH exons and introns when the inducer-bound transactivator occupies its operator sites.
A reverse tetracycline-responsive transactivator binds a tetracycline-class inducer and occupies operator sites upstream of the FAH promoter. Promoter activity falls after inducer withdrawal, and FAH abundance declines as the existing messenger RNA and protein turn over.
A tetracycline-responsive transactivator binds upstream operator sites and activates the FAH promoter in the absence of an inducer. Adding a tetracycline-class inducer prevents operator binding and lowers FAH transcription.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Generally, the expression vector will include a promoter. The promoter can be inducible or constitutive.B · US 2014/0373187 A1 · ¶ 171
If inducible, there are sequences present therein which mediate regulation of expression so that the associated sequence is transcribed only when an inducer molecule is present.A · US 2013/0007913 A1 · ¶ 112
The promoter can be inducible or constitutive.B · US 2014/0373187 A1 · ¶ 171
An empty cell means only that no passage was reproduced there.
There have been increasing threats from terrorists which present an urgent need for simple and robust detectors for harmful biological or chemical agents.A · US 2013/0007913 A1 · ¶ 5
The high and continuous cost significantly limits the ability to detect biological and chemical weapons as well as environmental pollutants.A · US 2013/0007913 A1 · ¶ 5
This disclosure also relates to methods of using such animal models, including expanding heterologous hepatocytes, such as human hepatocytes, in such animal models.B · US 2014/0373187 A1 · ¶ 5
The availability of high quality human hepatocytes is further hampered by the fact that they cannot be significantly expanded in tissue culture.B · US 2014/0373187 A1 · ¶ 8
patent.fyi, US 2026/0354358 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354358/, SHA-256 a45caa6005f7cd7029fbecd357059685dd6f536cb2b6ad37c026f3faaf92af5b